Please ensure Javascript is enabled for purposes of website accessibility

Psychedelic Therapeutics Company Mind Medicine Added to FTSE Indexes

By Eric Volkman - Mar 22, 2021 at 9:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock will be listed on both the FTSE Global Micro Cap and the FTSE Total Cap Indexes.

Two important stock indexes in the U.K. are going psychedelic. On Monday, Mind Medicine (MNMD 2.57%) announced that its stock will become a component of both the FTSE Global Micro Cap and the FTSE Total Cap Indexes, effective Friday, March 19.

Mind Medicine, or MindMed, is a clinical-stage biotech that concentrates on developing therapies based on psychedelic drugs like LSD and MDMA (better known as Ecstasy). The company has numerous projects in development, including one in which a precisely measured dose of LSD is administered by a therapist to help treat anxiety. That program is currently in front of a phase 2b human efficacy trial.

A doctor and a patient undergoing therapy.

Image source: Getty Images.

"Being included in mature and credible indexes like the FTSE Total Cap and FTSE Global Micro-Cap is a true honor," said Mind Medicine CEO J.R. Rahn. "As we build MindMed into a pioneering company for the long-term, our entire team looks forward to the potential positive change we can bring to treating mental health and addiction in the years ahead."

The FTSE indexes are widely considered to be the most important ones on the U.K. market. Fresh inclusion on any of them confers legitimacy on a stock and at a stroke raises its profile. Although this typically has little to no effect on a company's operations, that higher visibility can help improve investor sentiment.

Mind Medicine is a unique company and stock, and while massive rivals such as Johnson & Johnson (JNJ 2.04%) are exploring the therapeutic possibilities of psychedelic substances, it already has quite an extensive pipeline for such a small operator.

On the back of the FTSE news, Mind Medicine shares rose by nearly 1.1% Monday, topping the 0.7% increase of the S&P 500 index.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mind Medicine (MindMed) Inc. Stock Quote
Mind Medicine (MindMed) Inc.
MNMD
$0.79 (2.57%) $0.02
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$179.44 (2.04%) $3.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.